× Industry Reports Services Press Release Contact us About us

Europe Bioreactors Market Value to Gain USD 4.6 Bn by 2026

 Request a sample

According to the Graphical Research new growth forecast report titled Europe Bioreactors Market share is set to exceed USD 4.6 billion by 2026. With increasing prevalence of chronic and infectious diseases, the demand for effective medicines has also increased over period. The biopharmaceutical firms are continuously focusing on development of new drug therapies owing to the growing disease burden. Extensive applications of bioreactors in product development process boosts its adoption in manufacturing organizations. Thus, rising demand for pharmaceutical drugs will positively impact the bioreactors market growth in coming years.

Recent incidence of COVID-19 has affected millions of people in region that has influenced the demand for vaccines. The market players operating in the region are working with other organizations to expand their manufacturing facilities for vaccine and drug production to avoid supply shortage. Governments are also increasing funding to accelerate developmental process. For instance, the German government has announced the funding program for development and distribution of vaccine. Moreover, advancements in bioreactors helping manufacturers to cater striking demand will further stimulate the growth potential.

However, limited adoption of single-use systems due to issues regarding volume capacities and product quality can hamper its market growth upto some extent.

Reusable segment dominated the market with about 78% revenue share in 2019. Increasing adoption of reusable bioreactors in vaccines and monoclonal antibodies production due to advantage offered in high volume production will offer substantial growth opportunities to the segment. Further, benefits over single-use systems including ease in scale-up and scale-down during development process will fuel its revenue in the foreseeable future.

Bacterial cells segment accounted for over USD 265 million in 2019. The use of bacterial cells in bulk production of various pharmaceuticals and enzymes boosts its demand in coming years. Additionally, these cells are less susceptible to shear damage and offers high productivity. The advantage of bacterial cells such as enhanced nutrient and oxygen supply in bioreactor systems will foster the segmental growth in the future.

Monoclonal antibodies segment constituted about 33% market share in 2019 and is expected to grow robustly over projection period. The applications of monoclonal antibodies as therapeutics in cancer, arthritis, cardiovascular diseases and multiple sclerosis among several other diseases propels its revenue growth. Growing prevalence of such disorders results into bulk production of monoclonal antibodies that will further influence the bioreactors supply. Therefore, increasing product approvals pertaining to rising disease burden will offer unprecedented growth opportunities to bioreactors in the region.

R&D organizations held substantial 41% revenue share in 2019 and it is anticipated witness robust growth over the forecast period. High segment growth is primarily attributed to increasing funding and demand for effective health treatments. This has escalated the R&D activities in the region, thereby stimulating the demand for bioreactors. Furthermore, several industry players are investing more into research and development to attain competitive advantage. Bioreactors offers cost and performance associated benefits at R&D scale. Hence, owing to the aforementioned factors the segment will grow momentously.

UK bioreactors market is forecasted to grow at 13.8% CAGR during forecast timeframe. Growing biotechnology industry, increasing healthcare spending and presence of significant market players are some of the growth driving factors. The Biotechnology and Biological Sciences Research Council (BBSRC) is funding organization for bioscience training and research in the country. Such funding initiatives by national agencies stimulate the adoption of advanced products. Moreover, COVID-19 outbreak has further increased the development of pharmaceuticals that will impel the regional growth.

Major market players in market are Merck Group, Cytiva, Thermo Fisher Scientific, Eppendorf AG and Sartorius Group among others. These market players are undertaking various business development strategies such as product innovation, mergers and acquisition acquisitions to set their footprint in the region. For instance, in January 2020, Getinge acquired Applikon Biotechnology B.V. company that has been involved in manufacturing and supply of advanced bioreactors to biopharmaceutical industry. This strategy will strengthen market position of the firm with product portfolio expansion.

Europe Bioreactor Market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2015 to 2026, for the following segments:

Europe bioreactors Market Share, By Product Type, 2015-2026 (USD Million)

  • Single-use
  • Reusable

Europe bioreactors Market Size, By Cell, 2015-2026 (USD Million)

  • Mammalian Cells
  • Bacterial Cells
  • Yeast Cells
  • Others

Europe bioreactors Market Value, By Molecule, 2015 – 2026 (USD Million)

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Stem Cells
  • Gene Therapy
  • Others

Europe bioreactors Market Forecast, By End-user, 2015-2026 (USD Million)

  • R&D Organizations
  • Biopharmaceutical Manufacturers
  • Contract Manufacturing Organizations (CMOs)

The above information is provided for the following region and countries:

  • Europe
    • Germany
    • UK
    • Spain
    • Italy
    • France
    • The Netherlands
    • Denmark
    • Russia
    • Poland
    • Sweden
    • Norway
    • Others